Article info
PDFEditors’ commentary
Highlights of the issue
- Correspondence to Professor Philip E M Smith, University Hospital of Wales, Cardiff CF14 4XW, UK; SmithPE{at}cardiff.ac.uk
Citation
Highlights of the issue
Publication history
- Accepted April 15, 2019
- First published May 21, 2019.
Online issue publication
November 20, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease
- Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis
- Infectious encephalitis: mimics and chameleons
- CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
- Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations
- CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD
- Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease
- CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease
- Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination
- A practical approach to the diagnosis of spinal cord lesions